Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
abstract, Alan, Alex, Allied, attached, Brexit, certify, Colorado, Conference, Connecticut, conspiracy, construct, correlated, Counsel, coupled, curative, cyber, Dario, Derek, Dr, effectuated, ePrivacy, escalation, fraction, hacking, hereto, highest, highlight, highlighting, hybridization, hypothetical, incapacitated, infant, Intelligence, IRA, ISH, Jantz, Kelly, maximize, memory, mentally, newborn, outpace, poster, purport, regimen, Rescue, root, SCC, Scimeca, Secretary, simple, solution, stable, text, theft, tool, transduction, unsettled, Untied, Utah, Virginia, whichever
Filing tables
Filing exhibits
DTIL similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Precision BioSciences, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2022; as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 8, 2022 |
| By: | /s/ Michael Amoroso |
|
|
| Michael Amoroso |
|
|
| President, Chief Executive Officer and Director |
|
|
| (principal executive officer) |